Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by ImmunityBio, Inc.
< Previous
1
2
Next >
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
Today 8:30 EDT
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
April 21, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
April 15, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
April 08, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
April 07, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio to Host Investor Day
March 26, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
March 13, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
March 03, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
February 27, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
February 19, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
February 13, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
January 29, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces European Medicines Agency Acceptance of Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
January 27, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
January 15, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Provides Regulatory Update on Global Submission for ANKTIVA + BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ in Europe and United Kingdom
January 15, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
January 06, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
December 11, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
December 10, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
November 19, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Reports Third-Quarter 2024 Financial Results
November 12, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
October 24, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio to Participate in the Jefferies London Healthcare Conference
October 21, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
September 09, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
August 12, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
August 06, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
June 20, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
June 07, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
May 17, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
May 07, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
May 02, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Tickers
IBRX
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.